Anja Binckebanck

Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL)

Oliver G. Ottmann, Aristoteles Giagounidis, Matthias Stelljes et al. · Cancer · 2007 · 252 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

Anna Pavlova, Lydia Wunderle, Johannes Oldenburg et al. · Blood · 2007 · 249 citations · Full text

Medicine, Hematology, Oncology +12

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

Michael Stadler, Martin Bornhäuser, Gesine Bug et al. · Blood · 2005 · 199 citations · Full text

Medicine, Molecular Biology, Oncology +13

Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.

Wolf‐Karsten Hofmann, Martina Komor, Urban Scheuring et al. · PubMed · 2003 · 107 citations

Medicine, Oncology, Pharmacotherapy +16

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

Urban Scheuring, SA Klein, Nicola Gökbuget et al. · Leukemia · 2002 · 81 citations

Medicine, Oncology, Pharmacotherapy +15